[SCHEDULE 13G/A] CASI Pharmaceuticals, Inc. SEC Filing
Foresite Capital Fund VI, L.P., together with its general partner Foresite Capital Management VI, LLC and James Tananbaum, report beneficial ownership of 787,121 ordinary shares of CASI Pharmaceuticals, representing 5.1% of the outstanding class based on 15,492,581 shares outstanding. All 787,121 shares are reported as directly owned by Foresite Capital Fund VI, with the reporting persons asserting sole voting and sole dispositive power over those shares and no shared power. The filing includes a certification that the securities were not acquired to change or influence control of the issuer and indicates the holdings are held as passive investments. The filers executed a joint filing agreement.
Foresite Capital Fund VI, L.P., insieme al suo socio accomandatario Foresite Capital Management VI, LLC e a James Tananbaum, dichiara la propriet脿 beneficiaria di 787.121 azioni ordinarie di CASI Pharmaceuticals, pari al 5,1% della classe in circolazione su un totale di 15.492.581 azioni. Tutte le 787.121 azioni sono riportate come di propriet脿 diretta di Foresite Capital Fund VI; i soggetti segnalanti affermano di detenere potere di voto esclusivo e potere dispositivo esclusivo su tali azioni, senza alcun potere condiviso. La comunicazione include una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente e indica che le partecipazioni sono detenute come investimenti passivi. I firmatari hanno sottoscritto un accordo congiunto di deposito.
Foresite Capital Fund VI, L.P., junto con su socio general Foresite Capital Management VI, LLC y James Tananbaum, informa la tenencia beneficiaria de 787.121 acciones ordinarias de CASI Pharmaceuticals, que representan el 5,1% de la clase en circulaci贸n sobre un total de 15.492.581 acciones en circulaci贸n. Las 787.121 acciones se declaran como propiedad directa de Foresite Capital Fund VI, y las personas que presentan el informe afirman tener poder de voto exclusivo y poder dispositivo exclusivo sobre esas acciones, sin poder compartido. El documento incluye una certificaci贸n de que los valores no se adquirieron para cambiar o influir en el control del emisor e indica que las participaciones se mantienen como inversiones pasivas. Los declarantes firmaron un acuerdo conjunto de presentaci贸n.
Foresite Capital Fund VI, L.P.電� 攴� 鞚茧皹 韺岉姼雱� Foresite Capital Management VI, LLC 氚� James Tananbaum瓿� 頃粯 CASI Pharmaceuticals鞚� 787,121 氤错喌欤�鞐� 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤搓碃頄堨溂氅�, 鞚措姅 齑� 氚滍枆欤检嫕靾� 15,492,581欤茧ゼ 旮办鞙茧 頃措嫻 欤检嫕甑办潣 5.1%鞐� 頃措嫻頃╇媹雼�. 787,121欤茧姅 氇憪 Foresite Capital Fund VI臧� 歆侅爲 靻岇湢頃� 瓴冹溂搿� 氤搓碃霅橃棃瓿�, 氤搓碃鞚鸽摛鞚� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橂┌ 瓿奠湢 甓岉暅鞚� 鞐嗠嫟瓿� 欤检灔頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃橂姅 鞚胳靹滉皜 韽暔霅橃柎 鞛堨溂氅�, 氤挫湢 氇╈爜鞚� 靾橂彊鞝� 韴瀽(passive investment)鞛勳潉 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞛愲摛鞚� 瓿惦彊 鞝滌稖 瓿勳暯靹滌棎 靹滊獏頄堨姷雼堧嫟.
Foresite Capital Fund VI, L.P., conjointement avec son associ茅 commandit茅 Foresite Capital Management VI, LLC et James Tananbaum, d茅clare d茅tenir la propri茅t茅 b茅n茅ficiaire de 787 121 actions ordinaires de CASI Pharmaceuticals, repr茅sentant 5,1 % de la cat茅gorie en circulation sur la base de 15 492 581 actions en circulation. Les 787 121 actions sont d茅clar茅es comme 茅tant d茅tenues directement par Foresite Capital Fund VI ; les personnes d茅clarantes affirment d茅tenir le pouvoir de vote exclusif et le pouvoir de disposition exclusif sur ces actions, sans aucun pouvoir partag茅. Le d茅p么t comprend une certification indiquant que les titres n'ont pas 茅t茅 acquis pour modifier ou influencer le contr么le de l'茅metteur et pr茅cise que les participations sont d茅tenues 脿 titre d'investissements passifs. Les d茅clarants ont sign茅 un accord de d茅p么t conjoint.
Foresite Capital Fund VI, L.P., zusammen mit seinem pers枚nlich haftenden Gesellschafter Foresite Capital Management VI, LLC und James Tananbaum, meldet die wirtschaftliche Eigent眉merschaft an 787.121 Stammaktien von CASI Pharmaceuticals, was auf Basis von insgesamt 15.492.581 ausstehenden Aktien 5,1% der ausstehenden Klasse entspricht. Alle 787.121 Aktien werden als direktes Eigentum von Foresite Capital Fund VI angegeben; die meldepflichtigen Personen geben an, 眉ber diese Aktien alleiniges Stimmrecht und alleinige Verf眉gungsgewalt zu verf眉gen und keine geteilte Befugnis zu haben. Die Meldung enth盲lt eine Best盲tigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen, und weist darauf hin, dass die Beteiligungen als passive Investments gehalten werden. Die Melder haben eine gemeinsame Einreichungsvereinbarung unterzeichnet.
- Beneficial ownership of 787,121 shares (5.1% of class)
- Reporting persons assert sole voting and sole dispositive power over those shares
- Filing includes certification that holdings were not acquired to change or influence control (passive)
- None.
Insights
5.1% passive stake is material disclosure but indicates no intent to influence control; watch for future changes.
The filing discloses a 787,121-share position, equal to 5.1% of CASI's ordinary shares based on 15,492,581 shares outstanding. Because the reporting persons used Schedule 13G and certify the holdings were not acquired to influence control, this is presented as a passive ownership stake. The statement that sole voting and dispositive power is held by the general partner and the managing member clarifies who can exercise voting rights. For investors, the filing is a material ownership disclosure but contains no operational or control-related actions.
Sole voting/dispositive claims by the GP and managing member clarify authority; Schedule 13G signals passive intent.
The report identifies Foresite Capital Fund VI as the direct owner and names Foresite Capital Management VI and James Tananbaum as entities claiming sole voting and dispositive authority over the 787,121 shares. The joint filing agreement is noted, and the certification affirms the position is not intended to effect control changes. From a governance perspective, the disclosure clarifies who holds vote execution rights while indicating no declared activist intent, but it places the holder above the 5% reporting threshold, making it a publicly visible stakeholder.
Foresite Capital Fund VI, L.P., insieme al suo socio accomandatario Foresite Capital Management VI, LLC e a James Tananbaum, dichiara la propriet脿 beneficiaria di 787.121 azioni ordinarie di CASI Pharmaceuticals, pari al 5,1% della classe in circolazione su un totale di 15.492.581 azioni. Tutte le 787.121 azioni sono riportate come di propriet脿 diretta di Foresite Capital Fund VI; i soggetti segnalanti affermano di detenere potere di voto esclusivo e potere dispositivo esclusivo su tali azioni, senza alcun potere condiviso. La comunicazione include una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente e indica che le partecipazioni sono detenute come investimenti passivi. I firmatari hanno sottoscritto un accordo congiunto di deposito.
Foresite Capital Fund VI, L.P., junto con su socio general Foresite Capital Management VI, LLC y James Tananbaum, informa la tenencia beneficiaria de 787.121 acciones ordinarias de CASI Pharmaceuticals, que representan el 5,1% de la clase en circulaci贸n sobre un total de 15.492.581 acciones en circulaci贸n. Las 787.121 acciones se declaran como propiedad directa de Foresite Capital Fund VI, y las personas que presentan el informe afirman tener poder de voto exclusivo y poder dispositivo exclusivo sobre esas acciones, sin poder compartido. El documento incluye una certificaci贸n de que los valores no se adquirieron para cambiar o influir en el control del emisor e indica que las participaciones se mantienen como inversiones pasivas. Los declarantes firmaron un acuerdo conjunto de presentaci贸n.
Foresite Capital Fund VI, L.P.電� 攴� 鞚茧皹 韺岉姼雱� Foresite Capital Management VI, LLC 氚� James Tananbaum瓿� 頃粯 CASI Pharmaceuticals鞚� 787,121 氤错喌欤�鞐� 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤搓碃頄堨溂氅�, 鞚措姅 齑� 氚滍枆欤检嫕靾� 15,492,581欤茧ゼ 旮办鞙茧 頃措嫻 欤检嫕甑办潣 5.1%鞐� 頃措嫻頃╇媹雼�. 787,121欤茧姅 氇憪 Foresite Capital Fund VI臧� 歆侅爲 靻岇湢頃� 瓴冹溂搿� 氤搓碃霅橃棃瓿�, 氤搓碃鞚鸽摛鞚� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橂┌ 瓿奠湢 甓岉暅鞚� 鞐嗠嫟瓿� 欤检灔頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃橂姅 鞚胳靹滉皜 韽暔霅橃柎 鞛堨溂氅�, 氤挫湢 氇╈爜鞚� 靾橂彊鞝� 韴瀽(passive investment)鞛勳潉 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞛愲摛鞚� 瓿惦彊 鞝滌稖 瓿勳暯靹滌棎 靹滊獏頄堨姷雼堧嫟.
Foresite Capital Fund VI, L.P., conjointement avec son associ茅 commandit茅 Foresite Capital Management VI, LLC et James Tananbaum, d茅clare d茅tenir la propri茅t茅 b茅n茅ficiaire de 787 121 actions ordinaires de CASI Pharmaceuticals, repr茅sentant 5,1 % de la cat茅gorie en circulation sur la base de 15 492 581 actions en circulation. Les 787 121 actions sont d茅clar茅es comme 茅tant d茅tenues directement par Foresite Capital Fund VI ; les personnes d茅clarantes affirment d茅tenir le pouvoir de vote exclusif et le pouvoir de disposition exclusif sur ces actions, sans aucun pouvoir partag茅. Le d茅p么t comprend une certification indiquant que les titres n'ont pas 茅t茅 acquis pour modifier ou influencer le contr么le de l'茅metteur et pr茅cise que les participations sont d茅tenues 脿 titre d'investissements passifs. Les d茅clarants ont sign茅 un accord de d茅p么t conjoint.
Foresite Capital Fund VI, L.P., zusammen mit seinem pers枚nlich haftenden Gesellschafter Foresite Capital Management VI, LLC und James Tananbaum, meldet die wirtschaftliche Eigent眉merschaft an 787.121 Stammaktien von CASI Pharmaceuticals, was auf Basis von insgesamt 15.492.581 ausstehenden Aktien 5,1% der ausstehenden Klasse entspricht. Alle 787.121 Aktien werden als direktes Eigentum von Foresite Capital Fund VI angegeben; die meldepflichtigen Personen geben an, 眉ber diese Aktien alleiniges Stimmrecht und alleinige Verf眉gungsgewalt zu verf眉gen und keine geteilte Befugnis zu haben. Die Meldung enth盲lt eine Best盲tigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen, und weist darauf hin, dass die Beteiligungen als passive Investments gehalten werden. Die Melder haben eine gemeinsame Einreichungsvereinbarung unterzeichnet.
FAQ
How many CASI (CASI) shares does Foresite Capital Fund VI beneficially own?
What percentage of CASI does the 787,121-share position represent?
Who are the reporting persons in the CASI Schedule 13G/A?
Does the filing indicate the holders intend to influence CASI's control?
What voting and dispositive powers are reported over the CASI shares?
